113 related articles for article (PubMed ID: 31169219)
21. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
Qi YJ; Cui S; Yang YZ; Han JQ; Cai BJ; Sheng CF; Ma Y; Wuren T; Ge RL
J Cancer Res Ther; 2013; 9(3):410-5. PubMed ID: 24125975
[TBL] [Abstract][Full Text] [Related]
22. Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer.
Podmaniczky E; Fábián K; Pápay J; Puskás R; Gyulai M; Furák J; Tiszlavicz L; Losonczy G; Tímár J; Moldvay J
Pathol Oncol Res; 2015 Apr; 21(2):423-31. PubMed ID: 25194563
[TBL] [Abstract][Full Text] [Related]
23. The prognostic value of histological typing in nasopharyngeal carcinoma.
Cheung F; Chan O; Ng WT; Chan L; Lee A; Pang SW
Oral Oncol; 2012 May; 48(5):429-33. PubMed ID: 22177891
[TBL] [Abstract][Full Text] [Related]
24. Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma--correlation with excision repair cross-complementing-1 polymorphisms.
Ma BB; Hui EP; Wong SC; Tung SY; Yuen KK; King A; Chan SL; Leung SF; Kam MK; Yu BK; Zee B; Chan AT
Ann Oncol; 2009 Nov; 20(11):1854-9. PubMed ID: 19549713
[TBL] [Abstract][Full Text] [Related]
25. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.
Kuhlmann JD; Wimberger P; Bankfalvi A; Keller T; Schöler S; Aktas B; Buderath P; Hauch S; Otterbach F; Kimmig R; Kasimir-Bauer S
Clin Chem; 2014 Oct; 60(10):1282-9. PubMed ID: 25015375
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of ERCC1 in head and neck carcinoma treated with definitive or adjuvant radiotherapy.
Bišof V; Jakovčević A; Seiwerth S; Rakušić Z; Gašparov S
J Cancer Res Clin Oncol; 2013 Feb; 139(2):187-94. PubMed ID: 23011763
[TBL] [Abstract][Full Text] [Related]
27. Role of ERCC1 expression in colorectal adenoma-carcinoma sequence and relation to other mismatch repair proteins expression, clinicopathological features and prognosis in mucinous and non-mucinous colorectal carcinoma.
Foda AA; Palicelli A; Shebl A; Boldorini R; Elnaghi K; ElHawary AK
Indian J Pathol Microbiol; 2019; 62(3):405-412. PubMed ID: 31361228
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
Ota S; Ishii G; Goto K; Kubota K; Kim YH; Kojika M; Murata Y; Yamazaki M; Nishiwaki Y; Eguchi K; Ochiai A
Lung Cancer; 2009 Apr; 64(1):98-104. PubMed ID: 18823676
[TBL] [Abstract][Full Text] [Related]
29. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
[TBL] [Abstract][Full Text] [Related]
30. ERCC1 single nucleotide polymorphism C8092A, but not its expression is associated with survival of esophageal squamous cell carcinoma patients from Fujian province, China.
Chen WH; Xin PL; Pan QX; Chen YY; Wang CR; Zhang ZS; Chen YF; Zhang CY; Cai WJ
PLoS One; 2014; 9(9):e106600. PubMed ID: 25191856
[TBL] [Abstract][Full Text] [Related]
31. MiR-34c downregulation leads to SOX4 overexpression and cisplatin resistance in nasopharyngeal carcinoma.
Bissey PA; Teng M; Law JH; Shi W; Bruce JP; Petit V; Tsao SW; Yip KW; Liu FF
BMC Cancer; 2020 Jun; 20(1):597. PubMed ID: 32586280
[TBL] [Abstract][Full Text] [Related]
32. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G
Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186
[TBL] [Abstract][Full Text] [Related]
33. Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy.
Chen C; Wang F; Wang Z; Li C; Luo H; Liang Y; An X; Shao J; Li Y
Cancer Chemother Pharmacol; 2013 Aug; 72(2):315-22. PubMed ID: 23712330
[TBL] [Abstract][Full Text] [Related]
34. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer.
Steffensen KD; Waldstrøm M; Jeppesen U; Brandslund I; Jakobsen A
Int J Gynecol Cancer; 2008; 18(4):702-10. PubMed ID: 17961161
[TBL] [Abstract][Full Text] [Related]
35. TOP2A overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma.
Lan J; Huang HY; Lee SW; Chen TJ; Tai HC; Hsu HP; Chang KY; Li CF
Tumour Biol; 2014 Jan; 35(1):179-87. PubMed ID: 23897556
[TBL] [Abstract][Full Text] [Related]
36. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
[TBL] [Abstract][Full Text] [Related]
37. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients.
Takenaka T; Yano T; Kiyohara C; Miura N; Kouso H; Ohba T; Kometani T; Shoji F; Yoshino I; Maehara Y
Lung Cancer; 2010 Jan; 67(1):101-7. PubMed ID: 19361884
[TBL] [Abstract][Full Text] [Related]
38. Aberrant SATB1 expression is associated with Epstein-Barr virus infection, metastasis and survival in human nasopharyngeal cells and endemic nasopharyngeal carcinoma.
Deng YF; Zhou DN; Pan ZY; Yin P
Int J Clin Exp Pathol; 2014; 7(5):2454-61. PubMed ID: 24966956
[TBL] [Abstract][Full Text] [Related]
39. ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy.
Sun JM; Sung JY; Park SH; Kwon GY; Jeong BC; Seo SI; Jeon SS; Lee HM; Jo J; Choi HY; Lim HY
BMC Cancer; 2012 May; 12():187. PubMed ID: 22616552
[TBL] [Abstract][Full Text] [Related]
40. RPA3 is a potential marker of prognosis and radioresistance for nasopharyngeal carcinoma.
Qu C; Zhao Y; Feng G; Chen C; Tao Y; Zhou S; Liu S; Chang H; Zeng M; Xia Y
J Cell Mol Med; 2017 Nov; 21(11):2872-2883. PubMed ID: 28557284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
